Current challenges of biologic ADA analysis include requirements for increased assay drug tolerance often necessitating pre-treatment and lengthy protocols, coupled with decreased available sample volumes due to competition with PK and biomarker analysis, along with the need for automated methods to limit lab time and improve throughput. In this presentation, we present details of ADA analysis using a miniaturized, microfluidic immunoassay with automated acid dissociation pretreatment. Data from case studies are shown focusing on the high sensitivity, drug tolerance, and workflow optimization of the automated ADA approach, utilizing minimal sample volumes.
Understand the challenges of developing ligand-binding assays for reliable, drug-tolerant measurement of serum anti-drug antibodies in preclinical and clinical samples.
Learn about the CD-based, microfluidic immunoassay approach and advantages for ADA analysis.
Understand the workflow processes for manual and automated pre-assay acid dissociation and principles of ADA assay drug interference.